Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity
Satomi Shimura(National Institute of Infectious Diseases), Takaji Wakita(National Institute of Infectious Diseases), Sam‐Yong Park(Yokohama City University Medical Center), Ann E. Sluder(Massachusetts General Hospital), Yuki Ogasawara(Meiji Pharmaceutical University), Senko Tsukuda(National Institute of Infectious Diseases), Masaya Sugiyama(National Center for Global Health and Medicine), Camille Sureau(Génomes, biologie cellulaire et thérapeutiques), Masashi Iwamoto(Rockefeller University), Hiroyuki Kusuhara(The University of Tokyo), Michael Peel(Scynexis (United States)), Fumihiro Kawai(Yokohama City University), Takeshi Miyake(The University of Tokyo), Koichi Watashi(Tokyo University of Science), Kento Fukano(Meiji Pharmaceutical University), Junko S. Takeuchi(Institute for Security Studies), Masashi Mizokami(National Institute of Advanced Industrial Science and Technology), Yasuhito Tanaka(Kumamoto University)
Cited by 126
Related Papers
Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *
|Hepatology|2005|1.5k
The lipid droplet is an important organelle for hepatitis C virus production
|Nature Cell Biology|2007|1.2k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k